Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses increasing from $56.3 million to $77.5 million and G&A expenses rising from $15.1 million to $19.5 million [17][18] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024, driven by increased spending on clinical programs [17][18] - The company ended Q4 2025 with $926 million in cash and equivalents, a significant increase from $469 million at the end of 2024, bolstered by proceeds from public offerings [18][19] Business Line Data and Key Metrics Changes - The ulixacaltamide program reported positive results from the Essential3 program, leading to an NDA submission for essential tremor, with a potential market of over $10 billion annually [9][10] - The relutrigine program for SCN2A and SCN8A DEEs has an initial addressable population of approximately 10,000 patients, with potential annual revenue estimated at $5 billion [12] - Vormatrigine demonstrated a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with potential annual revenue exceeding $4 billion [14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, while the broader DEE population for relutrigine is over 200,000 patients [9][12] - The company is preparing for a significant commercial launch, focusing on disease awareness and inventory management for ulixacaltamide and relutrigine [22][31] Company Strategy and Development Direction - The company aims to transform into a commercial entity, with plans to submit two NDAs and enhance its clinical portfolio in 2026 [5][6] - A comprehensive medical education campaign is planned for the upcoming American Academy of Neurology annual meeting to raise awareness about ulixacaltamide [10][25] - The company is focused on building a strong commercial organization and ensuring sufficient inventory for product launches [22][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the potential for multiple readouts from the clinical pipeline and the importance of executing pre-commercial activities [16][17] - The company is well-capitalized with a strong balance sheet, expecting to fund operations into 2028 [19] - Management emphasized the importance of understanding the competitive landscape and the unmet needs in CNS disorders [10][12] Other Important Information - The company is planning an R&D day to discuss clinical programs and a commercial day to highlight launch strategies for ulixacaltamide and relutrigine [16] - Elsunersen is being developed for a rare genetic epilepsy, with a potential NDA submission expected next year [15][16] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness for ulixacaltamide [22] Question: What additional new data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for ulixacaltamide? - The company has proposed alternative titration schedules to the FDA and is awaiting their decision [29] Question: How much capital allocation should be expected between relutrigine and ulixacaltamide? - More allocation is expected for ulixacaltamide due to its broader market potential [31] Question: What is the review timeline for the NDAs? - The company has requested priority review for relutrigine but not for ulixacaltamide, considering strategic business reasons [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present long-term efficacy data to reinforce the value of ulixacaltamide [51] Question: What are the expectations for the EMBRAVE study? - The EMBRAVE study is expected to provide valuable data, with a focus on safety and efficacy [81][84]

人工智能正加速走进越来越多的应用场景。在科研领域，人工智能也逐渐深入核心环节，助推更多研究 成果加速涌现。今天，我们将通过近期我国科学家的一些突破性成果，来看人工智能怎样助力科研。首 先，让我们走进西湖大学，看人工智能如何协助科学家设计蛋白质，并精准锁定治疗疾病的靶点。 蛋白质既是生命活动的重要执行者，也是疾病治疗与药物研发的核心靶点。目前，人类已经发现的蛋白 质有2亿多种，但仍然无法满足我们的特定需要。因此，科研人员需要像设计师一样，根据功能和目标 去设计出特定的蛋白质，而这一过程极其复杂。在西湖大学，科研人员开发了一种全新的生成式大模 型，可以帮助他们从零开始设计具有全新功能的蛋白质。借助这一人工智能大模型，团队已取得多项新 发现，例如找到了一种有望用于治疗阿尔茨海默病的全新蛋白酶。 人工智能可以基于海量数据，构建出多种蛋白质结构与功能之间的对应关系。科研人员只需要设定好目 标和条件，大模型就能进行计算推演，并给出可能的蛋白质设计方案，供团队筛选与验证。 不过科研人员也指出，人工智能赋能蛋白质研究目前还存在技术局限。由于大多数的大模型训练数据主 要还是静态蛋白质结构数据，因此目前还难以模拟出蛋白质复杂动态 ...

Financial Performance - In early February 2026, AbbVie reported Q4 2025 sales of $16.6 billion, exceeding market expectations of $16.4 billion; adjusted EPS was $2.71, above the analyst average estimate of $2.65. The company raised its 2026 adjusted EPS guidance to a range of $14.37 to $14.57, higher than the market expectation of $14.22, reflecting confidence in this year's performance [1]. Business Developments - In Q4, Botox sales reached $717 million, marking the first growth since Q3 2024 and surpassing market expectations. The company implemented new marketing strategies, such as the "Naturally You" campaign, to revive its aesthetic business. However, Botox is included in the U.S. federal Medicare price negotiation list, which may lead to price adjustments starting in 2028 [2]. - The neuroscience segment generated $10.767 billion in revenue for 2025, a 19% year-over-year increase, making it the fastest-growing segment. AbbVie plans to strengthen its pipeline through internal R&D and external collaborations, including the acquisition of Cerevel Therapeutics, with a focus on Parkinson's disease therapies like Tavapadon, which has been submitted for approval [3]. - The oncology segment reported $6.655 billion in revenue for 2025, showing a slowdown in growth. However, new drugs performed well, with the global first c-Met ADC drug Teliso-V approved in May 2025, and sales of CD3×CD20 bispecific antibody Epkinly and FRα ADC drug Elahere increasing by 85.5% and 44%, respectively. The company completed over 10 transactions in 2025, totaling over $13 billion, and secured exclusive licensing for PD-1/VEGF bispecific antibody RC148 with Rongchang Bio in January 2026, further expanding its oncology pipeline [4]. - The immunology segment achieved $30.4 billion in revenue for 2025, a 14% year-over-year increase. Despite a decline in Humira sales due to patent expiration, new drugs Skyrizi and Rinvoq showed strong demand, with Q4 sales of $5 billion and $2.4 billion, respectively, supporting the business transition [5].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10]. Core Insights - The company has experienced a significant increase in new orders, driven by the demand for new drug research, with total new orders reaching 1.135 billion yuan in 2025, a year-on-year increase of 38.62% [5]. - The company is expected to incur a net loss attributable to shareholders of between -39.85 million yuan and -26.79 million yuan for the fiscal year 2025 [4]. - The company is in the process of acquiring a controlling stake in its subsidiary, which will enhance its capabilities in safety evaluation and clinical CRO services [9]. Summary by Sections Market Performance - The company’s stock price is currently at 57.99 yuan, with a total market capitalization of 8.2 billion yuan [1]. Order Growth - As of the end of 2025, the company’s backlog of orders increased to 1.248 billion yuan, a growth of 28.23% compared to the end of 2024 [5]. - The increase in orders is attributed to a recovery in the global and Chinese biopharmaceutical investment environment, with the healthcare sector seeing a financing amount of 122.779 billion yuan, up 46.41% year-on-year [5]. Financial Performance - The company’s net profit for Q4 2025 is projected to be between -25.06 million yuan and -12 million yuan, primarily due to the execution of low-price contracts from previous periods [6]. - The gross margin is expected to recover to over 30% as the industry’s demand and supply dynamics improve [6]. Strategic Projects - The company’s strategic project in Nantong has successfully launched, covering an area of 24,000 square meters and planning to build 130 international standard animal rooms [7]. - The Shanghai project is expected to complete its construction by Q1 2026, significantly enhancing the company’s order capacity [7]. Acquisition and Collaboration - The acquisition of the subsidiary will facilitate the integration of safety evaluation and clinical CRO services, creating a comprehensive service solution [9]. - The company has established a strategic partnership with YaoKang Bio to explore joint international pathways for animal and drug evaluation [9]. Earnings Forecast - Revenue projections for 2025, 2026, and 2027 are estimated at 792 million yuan, 1.098 billion yuan, and 1.402 billion yuan, respectively, with corresponding EPS of -0.23 yuan, 0.90 yuan, and 1.63 yuan [10].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [10] Core Insights - The company expects a significant increase in new orders driven by the demand for new drug research, with total new orders reaching 1.135 billion yuan in 2025, a year-on-year increase of 38.62% [5] - The company is set to recover from previous losses, with a projected net profit range for 2025 of -39.85 million to -26.79 million yuan, influenced by the execution of low-price contracts from prior periods [4][6] - The company is expanding its capacity with strategic projects, including a new facility in Nantong and ongoing construction in Shanghai, which will enhance its order-taking capabilities [7][9] Summary by Sections Financial Performance - The company reported a net profit of 5.52 million yuan in Q1 2025, a loss of 20.71 million yuan in Q2, and a profit of 0.40 million yuan in Q3, with an expected Q4 net profit ranging from -25.06 million to -12.00 million yuan [6] - The total revenue forecast for 2025-2027 is 792 million, 1.098 billion, and 1.402 billion yuan respectively, with EPS projected at -0.23, 0.90, and 1.63 yuan [10][12] Market Dynamics - The company is benefiting from a recovering investment environment in the biopharmaceutical sector, with a 46.41% year-on-year increase in financing in the healthcare sector, amounting to 122.779 billion yuan in 2025 [5] - The company has also strengthened its overseas market presence, with new orders from international markets totaling 74.772 million yuan, accounting for 6.59% of total orders [5] Strategic Initiatives - The company plans to acquire a controlling stake in its subsidiary, Yilin Si, which will enhance its capabilities in safety evaluation and clinical research, creating an integrated service solution [9] - A strategic partnership was established with YaoKang Bio in November 2025 to explore joint international pathways for animal testing and drug evaluation [9]

2026.02. 13 本文字数：1066，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市场 可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和加 拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲的药物研发管线停滞不前，加 之美国反疫苗政策的影响，过去一年赛诺菲股价下跌超过25%。 开发新药已被证明是赛诺菲最大的难题 ...

即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲的药物研发管线停滞不前， 加之美国反疫苗政策的影响，过去一年赛诺菲股价下跌超过25%。 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市 场可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和 加拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 不过葛丽鹤在默克任职期间，该公司在新药开发方面遭遇了许多挫折，仅三款新药进入市场。此外，尽 管她在不同领域有着广泛的经验，但市 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - Eli Lilly's new drug, Migalastat, has received approval from the National Medical Products Administration (NMPA) in China for the treatment of moderate to severe active Crohn's disease (CD) and ulcerative colitis (UC) in adults. This drug selectively inhibits the IL-23 pathway, which is involved in immune inflammatory responses [5]. - The pharmaceutical sector experienced a slight decline of -0.32% on February 11, 2025, underperforming the CSI 300 index by 0.10 percentage points, ranking 22nd among 31 sub-industries [4]. - Notable stock performances included Teva Biopharmaceuticals (+6.01%), ZhenDe Medical (+5.87%), and Keyuan Pharmaceutical (+5.79%) on the gainers' list, while Huakang Clean (-5.28%), Hualan Biologicals (-5.11%), and Qianyuan Pharmaceutical (-4.67%) led the decliners [4]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Industries: Neutral [3]

持股5%以上股东香塘集团于2025年11月至12月连续减持，包括2025年12月26日减持后持股比例降至5% 以下。该股东在两个月内发起多轮减持，市场担忧其可能进一步影响股价稳定性和公司治理信心。 产品研发进展 经济观察网根据公开信息，舒泰神（300204）在2026年初有以下值得关注的事件动态，主要涉及资本运 作、业绩表现、研发进展和股东行为等方面。这些事件基于公司公告和媒体报道整理，具体时间节点和 细节请以官方披露为准。 定增股票 舒泰神于2025年10月披露新一轮定增方案，计划募资不超过12.53亿元(其中8.83亿元用于创新药物研 发，3.7亿元补充流动资金)，该方案已获深交所受理。这是公司自2020年以来第四次推出定增，前三次 均终止，本次规模为上市以来最大，其审批结果可能对公司研发资金链产生重要影响。 业绩经营情况 2026年1月28日，公司发布2025年业绩预告，预计归属于上市公司股东的净利润为-8,532.76万元 至-6,981.35万元，亏损主要受核心产品舒泰清收入下降拖累，而苏肽生销量略有增长。正式年报预计在 2026年4月前披露，需关注实际亏损幅度及现金流改善情况。 股东减持 2025 ...

Core Viewpoint - The company has approved an internal restructuring of its fundraising investment projects to optimize the investment structure for its "new drug research and development projects" while keeping the total fundraising amount unchanged [1] Investment Structure Adjustment - The company will add the preclinical candidate drug "YF550" as a sub-project and reallocate funds among various sub-projects [1] - An additional investment of 232.1095 million yuan will be allocated to the oral TYK2 inhibitor D-2570 project to advance clinical trials for multiple autoimmune diseases, including psoriasis and ulcerative colitis [1] - New investments of 47.2 million yuan, 42.9 million yuan, and 20 million yuan will be made for the preclinical projects YF087, YF550, and exploratory research, respectively [1] - Funding for the URAT1 inhibitor D-0120 project will be reduced by 342.2095 million yuan [1] Strategic Focus - The adjustments aim to concentrate resources on core pipelines with faster research and development progress and greater market potential to enhance funding efficiency and accelerate product development [1] - The proposal is subject to approval at the company's shareholder meeting [1]